Published in Medical Letter on the CDC and FDA, June 13th, 2004
"Most people infected with Plasmodium vivax malaria developed antibodies against the C-terminal region of P. vivax merozoite surface protein (PvMSP1c) and the antibodies are sustained for a period up to 10 months after anti-malarial treatment. The longer-term stability of the specific humoral response was evaluated indirectly by determining the antibody titers in the sera from healthy individuals who lived an area from which malaria had been eradicated (450 persons) and an area in which it...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.